A KRAS-variant as a putative biomarker of ovarian cancer risk

被引：0
|
作者：
Weidhaas, Joanne B.
Slack, Frank
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-1856
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1856
引用
下载
收藏
页数：3
相关论文
共 50 条
  • [31] The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer
    Yousef, GM
    White, NMA
    Kurlender, L
    Michael, I
    Memari, N
    Robb, JD
    Katsaros, D
    Stephan, C
    Jung, K
    Diamandis, EP
    TUMOR BIOLOGY, 2004, 25 (5-6) : 221 - 227
  • [32] KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA)
    Berchuck, A.
    van der Baan, F. H.
    Johnatty, S. E.
    Chenevix-Trench, G.
    Pharoah, P. D. P.
    Rookus, M. A.
    Goode, E.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 26 - 27
  • [33] Association of the 3′-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Weidhaas, Joanne B.
    Lee, Ju-Whei
    Slebos, Robbert
    Howard, Jason
    Perez, Jimena
    Gilbert, Jill
    Nallur, Sunitha
    Paranjape, Trupti
    Garcia, Joaquin J.
    Burtness, Barbara
    Forastiere, Arlene A.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] A new biomarker for ovarian cancer
    Maduro, Maria Rosa
    REPRODUCTIVE SCIENCES, 2007, 14 (08) : 734 - 735
  • [35] Searching for a biomarker for ovarian cancer
    Roberts, JA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (08): : 739 - 739
  • [36] Biomarker discovery in ovarian cancer
    Tung, Celestine S.
    Wong, Kwong-Kwok
    Mok, Samuel C.
    WOMENS HEALTH, 2008, 4 (01) : 27 - 40
  • [37] Osteopontin as a biomarker for ovarian cancer
    Wallach, RC
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (24): : 3209 - 3209
  • [38] CD44 Variant 6 as a Biomarker for Distant Metastasis in Epithelial Ovarian Cancer Patients
    Motohara, T.
    Fujimoto, K.
    Narantuya, D.
    Sakaguchi, I.
    Tashiro, H.
    Katabuchi, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 83 - 83
  • [39] A KRAS microRNA binding site polymorphism as a novel biomarker of risk in triple negative breast cancer
    Paranjape, Trupti S.
    Heneghan, Helen
    Pelletier, Cory
    Hoffman, Aaron
    Kerin, Michael J.
    Harris, Lyndsay
    Zhu, Yong
    Miller, Nicola
    Zelterman, Daniel
    Tuck, David
    Slack, Frank
    Weidhaas, Joanne
    CANCER RESEARCH, 2010, 70
  • [40] A KRAS MICRORNA BINDING SITE VARIANT IS A GENETIC MARKER OF RISK FOR TRIPLE NEGATIVE BREAST CANCER
    Heneghan, H. M.
    Miller, N.
    Paranjape, T.
    Slack, F. J.
    Weidhaas, J. B.
    Kerin, M. J.
    EJC SUPPLEMENTS, 2010, 8 (06): : 16 - 16
12345